De Solidarite Des Travai Fonds Sells 47,854 Shares of enGene Holdings Inc. (NASDAQ:ENGN) Stock

enGene Holdings Inc. (NASDAQ:ENGN) major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of the firm’s stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $15.00, for a total transaction of $717,810.00. Following the sale, the insider now owns 3,036,153 shares of the company’s stock, valued at approximately $45,542,295. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

De Solidarite Des Travai Fonds also recently made the following trade(s):

• On Thursday, April 18th, De Solidarite Des Travai Fonds sold 4,575 shares of enGene stock. The stock was sold at an average price of $15.01, for a total value of $68,670.75.

enGene Trading Up 3.1 %

ENGN opened at $15.26 on Wednesday. enGene Holdings Inc. has a 12 month low of $6.69 and a 12 month high of $43.00. The business has a 50-day moving average of $16.27.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on ENGN shares. Leerink Partnrs reissued an “outperform” rating on shares of enGene in a research report on Tuesday, February 20th. Guggenheim began coverage on shares of enGene in a research note on Monday, April 15th. They set a “buy” rating and a $34.00 price objective for the company. Wells Fargo & Company started coverage on shares of enGene in a report on Monday. They issued an “overweight” rating and a $30.00 price target for the company. SVB Leerink started coverage on enGene in a report on Tuesday, February 20th. They issued an “outperform” rating and a $31.00 price target on the stock. Finally, Morgan Stanley initiated coverage on shares of enGene in a research report on Friday, March 8th. They set an “overweight” rating and a $40.00 target price for the company. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, enGene currently has an average rating of “Buy” and a consensus price target of $34.40.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Vivo Capital LLC purchased a new position in shares of enGene in the fourth quarter valued at about $6,264,000. Omega Fund Management LLC purchased a new position in enGene during the 4th quarter valued at about $10,441,000. BVF Inc. IL bought a new position in enGene during the 4th quarter valued at approximately $20,777,000. Finally, Fcpm Iii Services B.V. purchased a new stake in enGene in the 4th quarter worth approximately $80,097,000. Institutional investors own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.